Cardiac Sarcoidosis, Infective endocarditis
Conditions
Brief summary
Quantitative uptake of Al[18F]F-NOTA-folate measured by PET in the left ventricular myocardium in suspected cardiac sarcoidosis and in valvular regions in suspected infective endocarditis
Detailed description
Diagnostic performance of Al[18F]F-NOTA-folate PET for cardiac sarcoidosis and native or prosthetic valve infective endocarditis, Change in myocardial Al[18F]F-NOTA-folate uptake following immunosuppressive therapy in cardiac sarcoidosis, Biodistribution, stability, and radiation dosimetry of Al[18F]F-NOTA-folate in healthy volunteers, Incidence and severity of adverse events related to Al[18F]F-NOTA-folate
Interventions
DRUGAl[ 18 F]F-NOTA-folate
Sponsors
Turku University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative uptake of Al[18F]F-NOTA-folate measured by PET in the left ventricular myocardium in suspected cardiac sarcoidosis and in valvular regions in suspected infective endocarditis | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic performance of Al[18F]F-NOTA-folate PET for cardiac sarcoidosis and native or prosthetic valve infective endocarditis, Change in myocardial Al[18F]F-NOTA-folate uptake following immunosuppressive therapy in cardiac sarcoidosis, Biodistribution, stability, and radiation dosimetry of Al[18F]F-NOTA-folate in healthy volunteers, Incidence and severity of adverse events related to Al[18F]F-NOTA-folate | — |
Outcome results
None listed